Identification

Name
Candicidin
Accession Number
DB01152  (APRD00843)
Type
Small Molecule
Groups
Withdrawn
Description

Candicidin is an antibiotic obtained from a streptomyces (Streptomyces griseus) and active against some fungi of the genus Candida (C. albicans). Candicidin is administered intravaginally in the treatment of vulvovaginal candidiasis.

Synonyms
  • Candicidina
  • Candicidine
  • Candicidinum
  • Candizidin
International/Other Brands
Candicidin A / Candicidin D / FR-008-III / Prostatin
Categories
UNII
48N2IYJ202
CAS number
1403-17-4
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Used in the topical treatment of vulvovaginal candidiasis.

Structured Indications
Not Available
Pharmacodynamics

Candicidin is a polyene antifungal antibiotic produced by a strain of Streptomyces griseus. It is especially effective against Candida albicans (more effective than amphotericin B), and is administered intravaginally in the treatment of vulvovaginal candidiasis.

Mechanism of action

Ergosterol, the principal sterol in the fungal cytoplasmic membrane, is the target site of action of Candicidin. Candicidin binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death. There is some evidence that the binding site in the cell wall may be to fatty acids or fatty acid esters and that this binding capacity must be satisfied before candicidin can bring about its lethal effect by binding to sterol in the cell membrane.

TargetActionsOrganism
AErgosterol
antagonist
Candida albicans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Various Fungus Species
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AmlodipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Candicidin.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Candicidin is combined with Amrinone.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Candicidin is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Barnidipine.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Candicidin.Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Candicidin is combined with Bencyclane.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Benidipine.Approved, Investigational
BepridilThe risk or severity of adverse effects can be increased when Candicidin is combined with Bepridil.Approved, Withdrawn
BuspironeThe metabolism of Buspirone can be decreased when combined with Candicidin.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Candicidin.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Candicidin is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Candicidin is combined with Caroverine.Experimental
CilnidipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of adverse effects can be increased when Candicidin is combined with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Candicidin.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Clevidipine.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Candicidin.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Candicidin.Approved, Investigational, Vet Approved
DarodipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Darodipine.Experimental
DidanosineDidanosine can cause a decrease in the absorption of Candicidin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Candicidin is combined with Diltiazem.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Candicidin.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Candicidin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Candicidin is combined with Dotarizine.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Efonidipine.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Candicidin is combined with Eperisone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Candicidin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Candicidin is combined with Fendiline.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Candicidin is combined with Flunarizine.Approved
FosphenytoinThe serum concentration of Candicidin can be decreased when it is combined with Fosphenytoin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Candicidin is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Candicidin is combined with Gallopamil.Investigational
IsradipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Isradipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Candicidin is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Lercanidipine.Approved, Investigational
LidoflazineThe risk or severity of adverse effects can be increased when Candicidin is combined with Lidoflazine.Experimental
LosartanThe metabolism of Losartan can be decreased when combined with Candicidin.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Candicidin is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Manidipine.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Candicidin is combined with Mibefradil.Investigational, Withdrawn
NaftopidilThe risk or severity of adverse effects can be increased when Candicidin is combined with Naftopidil.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Candicidin is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Candicidin is combined with Nitrendipine.Approved, Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Candicidin is combined with Otilonium.Experimental, Investigational
PerhexilineThe risk or severity of adverse effects can be increased when Candicidin is combined with Perhexiline.Approved, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Candicidin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Candicidin.Approved
PimozideCandicidin may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Candicidin is combined with Pinaverium.Approved
PregabalinThe risk or severity of adverse effects can be increased when Candicidin is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Candicidin is combined with Prenylamine.Withdrawn
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Candicidin.Approved, Vet Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Candicidin.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Candicidin.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Candicidin.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Candicidin.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Candicidin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Candicidin.Approved, Investigational
RisedronateThe risk or severity of adverse effects can be increased when Candicidin is combined with Risedronate.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Candicidin.Approved
SucralfateSucralfate can cause a decrease in the absorption of Candicidin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Candicidin.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Candicidin.Approved, Investigational
TerodilineThe risk or severity of adverse effects can be increased when Candicidin is combined with Terodiline.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Candicidin is combined with Tetrahydropalmatine.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Candicidin is combined with Tolfenamic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Candicidin is combined with Tranilast.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Candicidin is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Candicidin is combined with Vinpocetine.Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Candicidin is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Candicidin is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Candicidin.Approved
Food Interactions
Not Available

References

Synthesis Reference

Siminoff, P.; U.S. Patent 2,872,373; February 3,1959; assigned to S.B. Penick & Company, Inc. Waksman, S.A. and Lechevalier, H.A.; U.S. Patent 2,992,162; July 11,1961; assigned to Rutgers Research and Educational Foundation.

General References
Not Available
External Links
Human Metabolome Database
HMDB15283
KEGG Drug
D03347
KEGG Compound
C06690
PubChem Substance
46504812
ChemSpider
10128184
ChEBI
354984
ChEMBL
CHEMBL1200647
Therapeutic Targets Database
DAP001325
PharmGKB
PA164754911
Wikipedia
Candicidin
ATC Codes
G01AA04 — Candicidin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP1.7Not Available
Predicted Properties
Not Available
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9509
Blood Brain Barrier-0.9398
Caco-2 permeable-0.7585
P-glycoprotein substrateSubstrate0.8004
P-glycoprotein inhibitor INon-inhibitor0.5359
P-glycoprotein inhibitor IIInhibitor0.6783
Renal organic cation transporterNon-inhibitor0.952
CYP450 2C9 substrateNon-substrate0.7747
CYP450 2D6 substrateNon-substrate0.8665
CYP450 3A4 substrateSubstrate0.5161
CYP450 1A2 substrateNon-inhibitor0.8668
CYP450 2C9 inhibitorNon-inhibitor0.9212
CYP450 2D6 inhibitorNon-inhibitor0.9092
CYP450 2C19 inhibitorNon-inhibitor0.8723
CYP450 3A4 inhibitorNon-inhibitor0.8064
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9525
Ames testNon AMES toxic0.8306
CarcinogenicityNon-carcinogens0.9559
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity2.5750 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9748
hERG inhibition (predictor II)Non-inhibitor0.7767
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

1. Ergosterol
Kind
Small molecule
Organism
Candida albicans
Pharmacological action
Yes
Actions
Antagonist
References
  1. Hammond SM, Kliger BN: Mode of action of the polyene antibiotic candicidin: binding factors in the wall of Candida albicans. Antimicrob Agents Chemother. 1976 Apr;9(4):561-8. [PubMed:773298]
  2. Brajtburg J, Elberg S, Kobayashi GS, Medoff G: Effects of serum lipoproteins on damage to erythrocytes and Candida albicans cells by polyene antibiotics. J Infect Dis. 1986 Mar;153(3):623-6. [PubMed:3512734]
  3. Borgers M: Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. Rev Infect Dis. 1980 Jul-Aug;2(4):520-34. [PubMed:7003674]

Drug created on June 13, 2005 07:24 / Updated on November 06, 2017 06:43